Text Size

Determination of Lymphocyte JAM-C Expression in Patients With Psoriasis Vulgaris

The recruitment status of this study is unknown because the information has not been verified recently.
Verified August 2009 by Johann Wolfgang Goethe University Hospitals.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Johann Wolfgang Goethe University Hospitals
ClinicalTrials.gov Identifier:
NCT00365625
First received: August 16, 2006
Last updated: February 1, 2010
Last verified: August 2009
History of Changes
  Purpose

The stepwise process of leukocyte extravasation to inflamed tissues depends on the expression of a variety of cytokines and adhesion molecules. Recently much attention has focused on the Junctional Adhesion Molecules (JAM). The three members of this adhesion molecule family, namely, JAM-A, -B and -C, have been shown to govern the last step of leukocyte extravasation (transmigration) - the process of leukocytes passing between endothelial cells. In addition to transmigration, some members of this family seem to support additional steps in the leukocyte extravasation cascade. The investigators recently showed, that antibody-mediated inhibition of JAM-C significantly reduced hapten induced skin inflammation (J Invest Dermatol;125(5):969).

Recent unpublished work from our laboratory showed, that JAM-C expression of lymphocytes can be up-regulated through specific activators. Hence, the investigators hypothesize, that JAM-C expression is elevated in patients with psoriasis. As it is currently not know, which factors may influence the expression of JAM-C, the investigators intend to analyse JAM-C expression on CD3+CD41- cells at several time-points during the treatment of psoriatic patients. Expression of JAM-C will then be correlated to disease activity (PASI).


Condition
Psoriasis
Psoriasis Vulgaris

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Patient Orientated Basic Science Investigation: Determination of Lymphocyte JAM-C Expression in Patients With Psoriasis Vulgaris

Resource links provided by NLM:

MedlinePlus related topics: Adhesions Psoriasis
U.S. FDA Resources

Further study details as provided by Johann Wolfgang Goethe University Hospitals:

Estimated Enrollment: 30
Study Start Date: July 2005
Estimated Study Completion Date: December 2007
Detailed Description:

The stepwise process of leukocyte extravasation to inflamed tissues depends on the expression of a variety of cytokines and adhesion molecules. Recently much attention has focused on the Junctional Adhesion Molecules (JAM). The three members of this adhesion molecule family, namely, JAM-A, -B and -C, have been shown to govern the last step of leukocyte extravasation (transmigration) - the process of leukocytes passing between endothelial cells. In addition to transmigration, some members of this family seem to support additional steps in the leukocyte extravasation cascade. We recently showed, that antibody-mediated inhibition of JAM-C significantly reduced hapten induced skin inflammation (J Invest Dermatol;125(5):969).

Recent unpublished work from our laboratory showed, that JAM-C expression of lymphocytes can be up-regulated through specific activators. Hence, we hypothesize, that JAM-C expression is elevated in patients with psoriasis. As it is currently not know, which factors may influence the expression of JAM-C, we intend to analyse JAM-C expression on CD3+CD41- cells at several time-points during the treatment of psoriatic patients. Expression of JAM-C will then be correlated to disease activity (PASI).

Detailed in- and exclusion criteria are outlined below.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

psoriasis patients

Criteria

Inclusion Criteria:

  • Psoriasis vulgaris
  • PASI >/= 10 at inclusion

Exclusion Criteria:

  • Psoriasis arthritis
  • Psoriasis pustulosa
  • Psoriasis palmoplantaris
  • Pregnancy
  • current infectious disease
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00365625

Contacts
Contact: Ralf J Ludwig, MD 0049-69-6301- ext 6162 r.ludwig@em.uni-frankfurt.de
Contact: Wolf-Henning Boehncke, Professor 0049-69-6301- ext 5743 boehncke@em.uni-frankfurt.de

Locations
Germany
Department of Dermatology - Clinic of the Johann Wolfgang Goethe University Recruiting
Frankfurt Am Main, Hessen, Germany, 60590
Contact: Ralf J Ludwig, MD     0049-69-6301- ext 6162     r.ludwig@em.uni-frankfurt.de    
Contact: Wolf-Henning Boehncke, Professor     0049-69-6301- ext 5743     boehncke@em.uni-frankfurt.de    
Sponsors and Collaborators
Johann Wolfgang Goethe University Hospitals
Investigators
Principal Investigator: Ralf J Ludwig, MD Department of Dermatology - Clinic of the Johann Wolfgang Goethe University
Study Chair: Roland Kaufmann, Professor Department of Dermatology - Clinic of the Johann Wolfgang Goethe University
Study Chair: Wolf-Henning Boehncke, Professor Department of Dermatology - Clinic of the Johann Wolfgang Goethe University
  More Information

Additional Information:
Homepage of the Department of Dermatology with all contact persons listed (site in German)  This link exits the ClinicalTrials.gov site

Publications:

Responsible Party: Prof. Ralf Ludwig, Johann Wolfgang Goethe University Hospitals
ClinicalTrials.gov Identifier: NCT00365625     History of Changes
Other Study ID Numbers: 244/06
Study First Received: August 16, 2006
Last Updated: February 1, 2010
Health Authority: Germany: Ethics Commission

Keywords provided by Johann Wolfgang Goethe University Hospitals:
Psoriasis
JAM3 protein, human
Cell Adhesion Molecules
 Skin
Inflammation
Lymphocytes

Additional relevant MeSH terms:
Psoriasis
Skin Diseases, Papulosquamous
Skin Diseases

ClinicalTrials.gov processed this record on May 19, 2013